Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection

This study has been completed.

Sponsor:

Collaborator:

Universitätsklinikum des Saarlandes

Information provided by:

FGK Clinical Research GmbH

ClinicalTrials.gov Identifier:

NCT00351403

First received: July 11, 2006

Last updated: February 5, 2010

Last verified: February 2010

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	January 2010
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

No publications provided by FGK Clinical Research GmbH

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology. 2011 Nov;141(5):1656-64. Epub 2011 Jul 22.

To Top